Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation

Tuerk, T R; Bandur, Stepan; Nuernberger, Jens; Kribben, Andreas; Mann, Klaus; Philipp, Th.; Heemann, Uwe; Viklický, Ondřej; Witzke, Oliver

doi:10.5414/cnp70026

Cited by 19 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…152 Gliquidone, a classic sulphonylurea, also showed effectiveness in treating PTDM in kidney transplant recipients, with a substantial improvement in FBG. 153 However, it should be noted that because of the risk of drug accumulation and hypoglycaemia, the use of sulphonylureas, particularly glyburide, is generally avoided in individuals with reduced eGFR. 154 To conclude, various antidiabetic medications, including oral…”

Section: Other Agentsmentioning

confidence: 99%

“…Similarly, repaglinide, a short‐acting insulin secretion drug, exhibited promise in treating PTDM after renal transplantation 152 . Gliquidone, a classic sulphonylurea, also showed effectiveness in treating PTDM in kidney transplant recipients, with a substantial improvement in FBG 153 . However, it should be noted that because of the risk of drug accumulation and hypoglycaemia, the use of sulphonylureas, particularly glyburide, is generally avoided in individuals with reduced eGFR 154 …”

Section: Management Strategies For Post‐transplant Diabetes Mellitusmentioning

confidence: 99%

See 1 more Smart Citation

An update review of post‐transplant diabetes mellitus: Concept, risk factors, clinical implications and management

Kanbay,

Copur,

Topçu

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

ObjectiveKidney transplantation is the gold standard therapeutic alternative for patients with end‐stage renal disease; nevertheless, it is not without potential complications leading to considerable morbidity and mortality such as post‐transplant diabetes mellitus (PTDM). This narrative review aims to comprehensively evaluate PTDM in terms of its diagnostic approach, underlying pathophysiological pathways, epidemiological data, and management strategies.MethodsArticles were retrieved from electronic databases using predefined search terms. Inclusion criteria encompassed studies investigating PTDM diagnosis, pathophysiology, epidemiology, and management strategies.ResultsPTDM emerges as a significant complication following kidney transplantation, influenced by various pathophysiological factors including peripheral insulin resistance, immunosuppressive medications, infections, and proinflammatory pathways. Despite discrepancies in prevalence estimates, PTDM poses substantial challenges to transplant. Diagnostic approaches, including traditional criteria such as fasting plasma glucose (FPG) and HbA1c, are limited in their ability to capture early PTDM manifestations. Oral glucose tolerance test (OGTT) emerges as a valuable tool, particularly in the early post‐transplant period. Management strategies for PTDM remain unclear, within sufficient evidence from large‐scale randomized clinical trials to guide optimal interventions. Nevertheless, glucose‐lowering agents and life style modifications constitute primary modalities for managing hyperglycemia in transplant recipients.DiscussionThe complex interplay between PTDM and the transplant process necessitates individualized diagnostic and management approaches. While early recognition and intervention are paramount, modifications to maintenance immunosuppressive regimens based solely on PTDM risk are not warranted, given the potential adverse consequences such as increased rejection risk. Further research is essential to refine management strategies and enhance outcomes for transplant recipients.

show abstract

Section: Other Agentsmentioning

confidence: 99%

Section: Management Strategies For Post‐transplant Diabetes Mellitusmentioning

confidence: 99%

An update review of post‐transplant diabetes mellitus: Concept, risk factors, clinical implications and management

Kanbay,

Copur,

Topçu

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Sulphonylureas did not change the cyclosporine pharmacokinetics in patients with PTDM [85]. Sulphonylureas are associated with an increased risk of hypoglycemia [86], in a study by Tuerk et al [87]. Gliquidone has proved as effective and safe as rosiglitazone PTDM.…”

Section: Sulphonylureasmentioning

confidence: 99%

Post-Transplant Diabetes: Prevalence, Risk, and Management Challenges

Bashier

Kumar

Alalawi

et al. 2022

Dubai Diabetes Endocrinol J

View full text Add to dashboard Cite

The prevalence of diabetes and diabetic nephropathy is increasing, especially in middle eastern countries. Many patients reach end-stage renal disease and either start dialysis or consider preemptive transplantation. Even a higher number of patients develop post-transplant diabetes, which imposes an even higher risk on graft survival and outcomes post-transplantation. Recently, in the UAE, a renal transplant service has been initiated. Because the population is considered at high risk for post-transplant diabetes, we wrote this review article to discuss the prevalence, risk factors, diagnostic criteria, and management, including lifestyle interventions, manipulation of immunosuppressant agents, and suggested algorithms for the use of oral hypoglycemic agents used in the management of post-transplantation diabetes mellitus. We also discussed the specific indications for each of the oral hypoglycemic agents.

show abstract

“…Sulfonylharnstoffe sowie Glinide sind die beim NODAT meisteingesetzten und auch die effektivsten OAD [25,27]. Sulfonylharnstoffe, Repaglinid und Nateglinid stimulieren die Sekretion von Insulin durch Hemmung der ATP-regulierten Kaliumkanäle in der Plasmamembran der Betazellen dosisabhängig.…”

Section: Therapieunclassified

“…Glinide haben eine deutlich kür-zere Halbwertszeit als Sulfonylharnstoffe und sollten nur vor den Hauptmahlzeiten eingenommen werden. Während von den Sulfonylharnstoffen nur Gliquidon bei einer GFR unter 30 ml/min zugelassen ist [15,27], können die Glinide auch bei schwerer Niereninsuffizienz eingesetzt werden. Allerdings werden beide Substanzen in der Leber durch verschiedene Isoenzyme des Cytochroms P450 metabolisiert.…”

Section: Therapieunclassified

Diabetes nach Nierentransplantation

Türk

Witzke

2011

Nephrologe

Self Cite

View full text Add to dashboard Cite

Diabetes mellitus (DM) nach Transplantation wurde zu Beginn derTransplantationsära erstmals beschrieben[23] und ist mit einem deutlich schlechteren Patienten-und Transplantatüberleben assoziiert [11]. Der Begriff "neu aufgetretener Diabetes mellitus nach Transplantation" ("new-onset diabetes mellitus after transplantation", NODAT) hat in den letzten Jahren den Begriff des Posttransplant-Diabetes-mellitus (PTDM) ersetzt [3], da dieser den neu aufgetretenen und transplantationsassoziierten DM deutlicher von schon vor Transplantation bestehendem DM abgrenzt. Diese Arbeit ist auf den NODAT fokussiert. Häufigkeit, Definition und Folgen des NODAT EpidemiologieNODAT ist eine oft auftretende Komplikation, dessen Häufigkeit angesichts der endemischen Adipositas und des zunehmenden Alters der Transplantatempfän-ger wahrscheinlich noch weiter zunehmen wird. Abhängig von der verwendeten Definition wird eine Inzidenz zwischen 2 und 50% berichtet. Legt man die nachfolgende Definition zugrunde und betrachtet die neueren großen epidemiologischen Studien, kommt man auf eine Inzidenz um 20% für NODAT und um 40% für abnorme Nüchternglukose oder gestörte Glukosetoleranz 12 Monate nach Nierentransplantation.

show abstract

Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation

Cited by 19 publications

References 0 publications

An update review of post‐transplant diabetes mellitus: Concept, risk factors, clinical implications and management

An update review of post‐transplant diabetes mellitus: Concept, risk factors, clinical implications and management

Post-Transplant Diabetes: Prevalence, Risk, and Management Challenges

Diabetes nach Nierentransplantation

Contact Info

Product

Resources

About